康师傅控股(00322.HK)拟2.03亿美元收购康师傅饮品5%股权持股升至82.9%
格隆汇12月20日丨康师傅控股(00322.HK)公布,于2019年12月20日,公司与顶新订立协议,据此,公司同意向顶新收购5.26万股康师傅饮品股份,代价为美元2.03亿元。出售股份占康师傅饮品已发行股本约5%。
康师傅饮品为公司的非全资附属公司。收购事项完成后,公司能够控制的康师傅饮品权益将由约77.9%增至约82.9%。康师傅饮品及其附属公司主要于中国从事生产及分销饮品产品。康师傅饮品于2017年度及2018年度分别取得净利润8.44亿元人民币及7.98亿元人民币。
公司称,收购事项将有助于公司进一步增加其于康师傅饮品的权益,并得以进一步发展饮品业务。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.